肝癌是全球第5大癌癥致死病因，發(fā)病率和死亡率居高不下。黃芪甲苷是黃芪中的關(guān)鍵活性成分，具有廣泛的藥理活性。黃芪甲苷通過(guò)抑制細(xì)胞增殖、誘導(dǎo)細(xì)胞凋亡、抑制細(xì)胞侵襲和遷移、調(diào)控能量代謝重編程、逆轉(zhuǎn)腫瘤多藥耐藥、調(diào)節(jié)機(jī)體免疫系統(tǒng)防治肝癌?？偨Y(jié)了黃芪甲苷抗肝癌的藥理作用研究進(jìn)展，以期為黃芪甲苷在肝癌精準(zhǔn)治療中的臨床轉(zhuǎn)化提供依據(jù)，并為抗腫瘤新藥研發(fā)提供思路。

Hepatocellular carcinoma is the fifth leading cause of cancer death in the world, with high incidence rate and mortality. Astragaloside IV is a key active ingredient in Astragali Radix, with a wide range of pharmacological activities. Astragaloside IV inhibits cell proliferation, induces cell apoptosis, suppresses cell invasion and migration, regulates energy metabolism reprogramming, reverses tumor multidrug resistance, and regulates the body's immune system to prevent and treat hepatocellular carcinoma. This article summarizes the research progress on the pharmacological effects of astragaloside IV against hepatocellular carcinoma, in order to provide a basis for the clinical translation of astragaloside IV in precision treatment on hepatocellular carcinoma and to provide ideas for the development of new anti-tumor drugs.

R285

黑龍江省自然科學(xué)基金計(jì)劃項(xiàng)目（LH2023H072，PL2024H244）